The report provides analysis of global Recombinant Plasma Protein Therapeutics market for the period 2016-2026, wherein 2019 to 2026 is the forecast period and 2017 is considered as the base year. According to Acumen Research and Consulting, the global Recombinant Plasma Protein Therapeutics market is expected to grow at noteworthy CAGR around 8.3 % throughout the forecast period and reach around US$ 17.1 billion by 2026. Replacing recombinant plasma products for plasma - derived proteins, increasing product launch and the demand for novel hemophilia therapy is forecast to drive the market.
Based on drug class, cell line and indication, the global recombinant plasma protein therapy market is segmented. Based on the drug class, recombinant coagulation factors and the human C1 esterase inhibitor are classified on the market. In addition, recombinant cloturing factor VIII, recombinant coagulation factor VIIa, recombinant coagulation factor IX, and others, were divided into segment. The VIII subsegment of recombinant coagulation factor is expected to account for a major share of the market segment's recombinant coagulation by 2026, due to the growth of the number of global hemophilia A cases, new product launch and recombinant plasma protein therapy for the use of hemophilia A. During the forecast period, the recombined coagulation factor VIIa subsegment is expected to expand steadily. As far as the cell line is concerned, the market is divided into the Chinese cell line hamster ovary, the Baby Hamster cell line (BHK), the human embryonic cell line kidney (HEK) and other cell lines. The cell-line segment of Chinese hamster ovary (CHO) is expected to be extended in a prominent CAGR because the use of CHO cell lines for therapeutic products has increased. Based on the indications, hemophilia A, B, Von Willebrand and others were segregated from the market.
Various factors such as shifting from plasma based protein use to recombinant therapy, increasing awareness about rare diseases management, and increasing focus on investment in rare diseases are driving the global recombinant plasma protein therapy market. Furthermore, a continuous increase will lead to a significant market trend in the forecast phase in patients with rare hematological conditions and product approval from regulators like FDA, the European Commission and the Ministry of Health, Labor and Welfare (Japan). The high cost of treatment and alternative treatments are nevertheless likely to curb the market. On the other hand, the plasma protein therapeutics sector has grown profitably in the past decade, with immunoglobulin capturing the biggest share in the market. The demand for plasma products stems from the increasing prevalence of diseases, geriatrics and increased drug access in emerging markets. New plasma-based therapy approvals are expected to fuel demand more. New investment avenues for global market giants are offered by developing countries such as China and Brazil.
In order to increase market penetration of plasma proteins, the development of new products with clinical benefits such as increased efficacy and simple sample plasma extraction techniques is expected. In Asia Pacific, a strong demand for albumins and higher use of immunoglobulin are projected to push the market throughout the forecast period.
Increased number of market drive regulatory approvals
In the last three years, the availability of various options for patients with rare diseases, like hemophilia and other bleeding disorders has been increasing in the number of regulation approved. These approvals allowed firms to expand and benefit from their product portfolios. For example, CSL Behrings AFSTYLA, a recombinant factor of VIII indicated to treat hemophilia A in September 2017, was approved by the Ministry of Health, Labor and Welfare, Japan. In the United States, Canada, and Switzerland, AFSTYLA has also been approved. The VONVENDI recombinant von Willebrand factor was approved by Shire in April 2018 for perioperative bleeding management for VOLLEbrand disease patients in FDA (Food and Drug Administration). Bayer AG announced in July 2018 that it has approved Kovaltry, a recombinant factor VIII for hemophilia A treatment from the regulatory authorities in China.
On the regional basis, North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa are the global recombinant plasma protein therapeutic markets. North America is expected to have a significant global market share. As demand for recompound coagulation factor VII and IX is growing, the US market will expand at rapid rates, with a growing number of market players offering recombinant plasma proteins and an increased focus on management of rare diseases, such as hemophilia A, hamophilia B and von Willebrand disease.
In Europe, increasing numbers have gathered funding for research and development studies into recombinant DNA technology in established biotechnology and pharmaceutical companies and research institutes, universities and business players, and this in turn is intended to boost the market. Further, the development of new disease therapeutic products has significantly been driven by advances in genetic engineering and biotechnology in countries such as Germany, the United Kingdom and France. In addition, in January 2017, the European Commission granted CSL Limited approval to the treatment of Hemophilia A and marketing authorisation for AFSTYLA. In addition to these approves, CSL Limited received the European Commission's approval and marketing authorisations for the AFSTYLA treatment of hemophilia A in January 2017.
Recombinant Plasma Protein Therapeutics Market by Drug Class
Recombinant Plasma Protein Therapeutics Market by Cell Line
Recombinant Plasma Protein Therapeutics Market by Indication
Global Recombinant Plasma Protein Therapeutics Market, by Geography
The market research study on “Recombinant Plasma Protein Therapeutics Market (By Drug Class: Human C1 Esterase Inhibitor, Recombinant Coagulation Factors; By Cell Line: Chinese Hamster Ovary (CHO) Cell Line, Human Embryonic Kidney (HEK) Cell Line, Baby Hamster Kidney (BHK) Cell Line, Others; By Indication: Hemophilia B, Hemophilia A, Von Willebrand Disease) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Recombinant Plasma Protein Therapeutics market segments with market dynamics and their impact. The report provides insights on global Recombinant Plasma Protein Therapeutics market by Drug Class, by Cell Line, and major geographic regions. The report also covers basic technology development policies.
The report offers an overview of the market and statistical diagrams to support the expected figures. Our analysts predict the market scope and future prospects in an insightful way. The Acumen Research and Consulting report contains a comprehensive analysis of the global market in Recombinant Plasma Protein Therapeutics segmented. The report outlines numerous growth strategies implemented by companies as well as the latest market trends. The market share and current position of all leading players are discussed in detail. It analyzes players ' new revenue sources and highlights the different strategies.
Key Players and Strategies
The Recombinant Plasma Protein Therapeutics market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are Octapharma, Novo Nordisk A / S, Bayer AG, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharma Group NV, Pfizer Inc., and CSL Limited, Shire (Takeda Pharmaceutical Company Limited) among others.
With the attendance of many small and medium-sized manufacturers, the market is fragmented. The strong presence of local manufacturers and suppliers, particularly in North America, is one of the main reasons for market fragmentation. In addition, companies focus on product adaptation, strategic partnerships and new customer acquisitions to gain more market shares.
These companies are able to expand their global market presence through new product launch, purchasing, geographical expansion, collaborations and distribution agreements. Takeda Pharmaceutical Company Limited, a pharmaceutical company based in Japan, was acquired by Shire in January 2019. This acquisition aims to strengthen the geographic presence of Takeda Pharmaceutical Company Limited. Bioverativ Therapeutics Inc., which operates as part of Sanofi Genzyme, has been acquired by Sanofi, the leading pharmaceutical company, in January 2018. Many other players on the market have also taken steps to expand their business in emerging markets. Leading players in the Asia Pacific, such as China, Japan and Australia, also concentrate on increasing their customer base. Market participants are also supporting several campaigns to increase awareness about hematological disorder and the availability and advantages offered by such products of treatments, such as recombinant plasma proteins.